Core Laboratories Joint Venture Agreement
VIBGYOR Scientific Research, genae associates, Cardiovascular Center Aalst and J.B. Dahm, MD have reached an agreement to form a Core Laboratories joint venture, called imaeon.
Core Laboratories joint venture agreement between genae associates, VIBGYOR Scientific Research, Cardiovascular Center Aalst and J.B. Dahm
6 October 2008 - Antwerp, Ahmedabad, Aalst, Göttingen
VIBGYOR Scientific Research, genae associates, Cardiovascular Center Aalst and J.B. Dahm, MD have reached an agreement to form a Core Laboratories joint venture, called imaeon.
imaeon initially will focus on the performance of medical images analysis for clinical research projects, including but not limited to: quantitative coronary and peripheral angiography (QCA, QVA), computed tomography (CT) angiography, intravascular ultrasound (IVUS) and IVUS related
techniques, multiple gated acquisition scan (MUGA), optical coherence tomography (OCT), magnetic resonance imaging (MRI), multi slice computer tomography (MSCT), electrocardiogram (ECG) and ECHO assessments.
While meeting or exceeding all quality standards in a timely and cost-effective manner, imaeon will offer expert evaluations of medical images from multi-modality environments and unsurpassed quality clinical research services. It will operate from the main facilities and offices in Ahmedabad,
India and from the subsidiary in Antwerp, Belgium and focus on the pharmaceutical, biomedical and medical device industries.
About Cardiovasculair Onderzoek Aalst CVBA
Cardiovasculair Onderzoek Aalst, with principal offices in Aalst, Belgium, provides consultancy assignments and logistics support related to scientific research and scientific studies for physicians, hospitals, universities, pharmaceutical institutions, governments and governmental institutions.
Contact
Paul Nellens, MD - paul.nellens@olvz-aalst.be
About genae associates nv
genae is a privately held NV/SA with principal offices in Antwerp, Belgium and is ISO 9001:2000 certified for CRO, Core Laboratories and Services Provider for the Medical Industries. These global services include but are not limited to Clinical Data Management, Electronic Data Capture
(EDC), Statistical Analysis, Scientific & Medical Writing, CE-Marking (MDD) and Training & Education.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Ponsegromab Significantly Improves Body Weight in Patients with Cancer Cachexia
September 17th 2024Results of a Phase II study of ponsegromab showed significant improvements in body weight, muscle function, and overall symptoms for patients with cancer cachexia, offering hope for a new targeted treatment.
Imfinzi Plus Imjudo Shows Significant Five-Year Survival Improvement in Unresectable Liver Cancer
September 16th 2024Data from the Phase III HIMALAYA trial found the combination of Imfinzi plus Imjudo reduced the risk of death by 24% compared to sorafenib in patients with unresectable hepatocellular carcinoma.
